Shots:

• MiNA to receive $267.6M in up front- exclusivity fee on first neurological target and will be eligible to receive research- development- regulatory and commercial milestones along with royalties
• Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration
• The collaboration integrates Servier’s CNS expertise and MiNA’s small activating RNA technology to identify new potential treatments for restoring normal cell function in neurological disorders

 ­ Ref: Businesswire| Image: Nohat